Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146029 · ClinicalTrials.gov registry record
Companion Pharmacogenetic Study to UMCC 9900/9901
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
NCT00146029 is a clinical trial that was terminated before completion, run by University of Michigan Rogel Cancer Center.
The verdict
NCT00146029 was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
Study Summary
The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.
Trial Details
| Field | Value |
|---|
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00146029
The ClinicalTrials.gov registry entry for NCT00146029 describes a study currently listed as terminated, categorized as an unspecified phase. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00146029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00146029 about?
NCT00146029 is a clinical study titled "Companion Pharmacogenetic Study to UMCC 9900/9901". The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that...
What is the current status of trial NCT00146029?
This trial is currently terminated.
Who is sponsoring clinical trial NCT00146029?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.